ClinicalTrials.gg
CompletedNCT03997760RAISEUpdated Apr 23, 2024Results posted

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease

A Phase 1 interventional study of TAK-755 and Placebo in Sickle Cell Disease, sponsored by Shire. Completed at 14 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
384th of 559
19 · median 31
Started
2019
with 35 others
Phase 1
98 of 733
13 open now
Registered
457th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 384th largest by enrollment of the 559 interventional ones that give a count, is one of 36 that started in 2019, is one of 98 in phase 1, and was the 457th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

TAK-755 (previously known as SHP655) is a medicine used to treat sickle cell disease (SCD). The main aim of the study is to measure the safety and tolerability of TAK-755 in SCD participants.

Study participants will receive TAK-755 or placebo on Day 1. Their SCD will be treated by their doctor according to their doctor's usual clinical practice.

During the study, participants will be asked to follow-up on 13 days following SHP655 or placebo administration for safety assessment. Maximum duration of participation is expected to be about 2 months.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years at the time of signing the .
  • An understanding, ability, and willingness to fully comply with study procedures and requirements.
  • Ability to voluntarily provide written, signed, and dated (personally or via a legally authorized representative) informed consent to participate in the study.
  • Male or female with a documented history of HbSS or HbSβo thalassemia (based on clinical record of genetic, electrophoresis, or high-performance liquid chromatography testing).
  • Participant currently taking hydroxyurea must be on a stable dosing for 3 months at screening.

Exclusion criteria

Exclusion Criteria:

  • The participant was diagnosed with acute VOC in the 21 days before dosing on Day 1.
  • The participant has undergone blood transfusion within the last 30 days or blood transfusion on greater than or equal to (>=) 2 occasions in the last 90 days, at Screening Visit.
  • The participant has a history of acquired or congenital thrombotic thrombocytopenic purpura.
  • The participant has serum creatinine level greater than (>) 1.2 milligrams per deciliter (mg/dL).
  • The participant has >3* (based on clinical laboratory normal range), direct level >2 mg/dL, or indirect bilirubin level >5 mg/dL at the Screening Visit.
  • The participant has a level \<5 grams per deciliter (g/dL) at the Screening Visit.
  • The participant has a count of \<100 000/cubic millimeter (mm\^3) at the Screening Visit.
  • Signs or symptoms of infection requiring treatment with IV antibiotics during the Screening Period.
  • The participant has fever with body temperature of >=38.5 degree Celsius (ºC) (101.3 degree Fahrenheit [ºF]) at the Screening Visit or before dosing on Day 1.
  • The participant has Acute Chest Syndrome (ACS), diagnosed or strongly suspected, as evidenced by a new infiltrate on chest radiograph, and one or more of the following criteria:

    1. Fever with body temperature >39°C (102.2°F)
    2. Hypoxia (confirmed by arterial blood gases with partial pressure of arterial oxygen (PaO2) \<70 millimeter of mercury [mmHg])
    3. Chest pain
    4. Suspicious findings on physical examination (tachypnea, intercostal retraction, wheezing, and/or rales)
  • The participant has recently (within the past 28 days, from Screening Visit) undergone major surgery, requires hospitalization, documented serious bacterial infection requiring antibiotic treatment, or significant bleeding.
  • The participant has had a recent (within the past 90 days, from Screening Visit) episode of stroke, , symptomatic pulmonary hypertension, or seizure.
  • Any history of hemorrhagic stroke or bleeding diathesis.
  • The participant has received any of the following protocol-restricted medicines: a) systemic therapy within 48 hours before dosing, or there is the expectation that such therapy may be given during the study (inhaled or topical steroids are allowed); b) Anticoagulant or antiplatelet therapy within the past 3 weeks before dosing; c) crizanlizumab within the past 30 days before dosing; d) voxelotor within the past 14 days before dosing.
  • For participants receiving chronic or long-acting opioids, a change in dose or pain requiring medical attention in the past 14 days before dosing.
  • The participant has a medical or psychiatric condition that, in the opinion of the investigator, may pose a risk to the participant for participation or interfere with the conduct or results of the study.
  • The participant has received or plans to receive any other agent within the 4 weeks prior to the study screening visit or during the course of the study.
  • There is the expectation that the participant will not be able to be followed for the duration of the study.
  • The participant is pregnant or lactating or a female of or male unable or unwilling to comply with methods or abstinence until the end of study visit.
  • The participant with active use of illicit drugs (excluding marijuana) and/or alcohol dependence, as determined by the investigator.
  • The participant has been administered SHP655 previously.
  • Known life-threatening reaction, including anaphylaxis, to the parent molecule ADAMTS-13, hamster protein, or other constituents of SHP655.
  • The participant has a positive test result for surface antigen, or antibody, or (HIV) antigen/antibody, at the Screening Visit. However, a participant with a hepatitis C antibody and a negative hepatitis C virus ribonucleic acid (RNA) polymerase chain reaction test is not excluded.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    TAK-755

    Participants with SCD at their baseline health will receive a single intravenous (IV) infusion at one of the 3 dose levels of 40, 80 and 160 International units per kilogram (IU/kg) in a dose escalation manner.

    Drug: TAK-755

  • Placebo comparator
    Placebo

    Participants with SCD at their baseline health will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.

    Other: Placebo

Interventions

  • Participants will receive TAK-755 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.

    Also known as: recombinant ADAMTS13, BAX 930, SHP655

  • OtherPlacebo

    Participants will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product (IP) or medicinal product. TEAEs were defined as AEs that started or worsened in severity on or after the infusion of IP. A serious TEAEs was any untoward clinical manifestation of signs, symptoms or outcomes (whether considered related to investigational product or not and at any dose) which resulted in death, was life-threatening, required inpatient hospitalization, prolongation of hospitalization, was an important medical event. TEAEs included both serious and non-serious AEs.

    Time frame: From date of signing informed consent up to end of study visit (Day 28)

  2. Number of Participants Who Developed Positive Binding Anti-ADAMTS13 and Inhibitory Anti-ADAMTS13 Antibodies to TAK-755

    Measurement of Anti-ADAMTS13 antibodies can be used to assess whether the body's immune system has been stimulated to react to TAK-755. Binding Anti-ADAMTS13 antibodies measure antibodies that are able to bind to ADAMTS13, whether or not the antibodies have an effect on how well ADAMTS13 works. An inhibitory Anti-ADAMTS13 antibody is antibody that both binds to ADAMTS13 and able to affect how well ADAMTS13 works. Binding and Inhibitory anti-ADAMTS13 antibodies were categorized as pre-existing, treatment-induced, and treatment-boosted. Pre-existing: anti-ADAMTS13 antibodies were detected in the baseline sample prior to infusion with TAK-755. Treatment-induced: no anti-ADAMTS13 antibodies were detected in baseline sample but were detected in any sample drawn after TAK-755 infusion. Treatment-boosted: anti-ADAMTS13 antibodies were pre-existing and were detected at any time after TAK-755 infusion at titers that were at least 4 steps higher than the titers detected before TAK-755 infusion.

    Time frame: From date of signing informed consent up to end of study visit (Day 28)

Secondary outcomes

  1. Incremental Recovery (IR) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

    IR was defined as the ratio of maximum increase in plasma ADAMTS13 antigen or activity level to TAK-755 dose per body weight. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall. Here "IU/mL/IU/kg" refers to "International units per milliliter per international units per kilogram".

    Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose

  2. Observed Maximum Concentration (Cmax) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

    Cmax was a measure of the maximum amount of drug in the plasma after the dose was given. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

    Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose

  3. Time to Reach Cmax (Tmax) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

    Tmax was a measure of the time to reach the maximum concentration in the plasma after the drug dose. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

    Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose

  4. Terminal Half-Life (t1/2) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

    t1/2 was the time required for a given drug concentration in the plasma to decrease by 50%. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

    Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose

  5. Mean Residence Time From Zero to Infinite (MRT0-Inf) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

    The MRT is the average time that the study product stays in the body (or plasma). The MRT0-Inf is defined as the average time from zero (pre-dose) extrapolated to infinite time (MRT0-inf). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

    Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose

  6. Mean Residence Time From Zero to 72 Hours Post-dose (MRT0-72) of ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

    The MRT is the average time that the study product stays in the body (or plasma) and The MRT0-72 is defined as the average time from zero (predose) to 72 hours post-dose (MRT0-72). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755.

    Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, and 72 hours post-dose

  7. Area Under the Curve From Zero to Time of Last Quantifiable Concentration (AUC0-Last) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

    AUC0-Last was an area under the concentration-time curve from zero (pre-dose) to time of last quantifiable concentration. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

    Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose

  8. Area Under the Curve Time Curve From Zero to 72 Hours Post-dose (AUC0-72) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

    AUC0-72 was an area under the concentration-time curve from zero (predose) to 72 hours post-dose (AUC0-72). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

    Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, and 72 hours post-dose

  9. Area Under the Curve From Zero to Infinite Time (AUC0-Inf) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

    AUC0-inf was area under the concentration-time curve from zero (pre-dose) extrapolated to infinite time. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

    Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose

  10. Systemic Clearance (CL) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

    CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC\[0-infinity\]). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

    Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose

  11. Volume of Distribution at Steady State (Vss) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

    Vss is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by MRT(0-inf)\*CL. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

    Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose

  12. Change From Baseline in Von Willebrand Factor: Antigen (VWF:Ag) at Specified Timepoints

    Von Willebrand factor (vWF or VWF) is a protein that is one of several components of the coagulation system that work together to stop bleeding within the body. VWF:Ag measures the level of von Willebrand factor protein in the blood. The change from baseline in VWF:Ag concentration was measured at different time points. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.

    Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose

  13. Change From Baseline in Von Willebrand Factor:Ristocetin Cofactor Activity (VWF:RCo) At Specified Timepoints

    Von Willebrand factor (vWF or VWF) is a protein that is one of several components of the coagulation system that work together, to stop bleeding within the body. VWF:RCo assay is a test that measures the activity of the VWF in a plasma sample in terms of how well it is able to clump platelets together in the presence of the antibiotic ristocetin. Change from baseline in vWF:RCo concentration was measured at different timepoints. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.

    Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose

  14. Change From Baseline in Platelet Count at Specified Timepoints

    Blood samples were collected to analyze platelet count. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Thechange from baseline was calculated by subtracting the baseline value from the post-dose value.

    Time frame: Baseline (Pre-dose), 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose

  15. Change From Baseline in Plasma Free Hemoglobin at Specified Timepoints

    The plasma free hemoglobin test measures the level of hemoglobin in the plasma (that is, not contained within the red blood cells). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.

    Time frame: Baseline (Pre-dose), 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose

  16. Change From Baseline in Plasma Thrombospondin Levels at Specified Timepoints

    Change from baseline in plasma thrombospondin levels over time was reported. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.

    Time frame: Baseline (Pre-dose), 3, 8, 24, 72, 120, 168, 288, and 648 hours post-dose

07

Results

Posted Apr 23, 2024

Participant flow

This study was conducted at 9 active sites in the United States from 21 October 2019 to 26 October 2022.

Participant flow — Overall Study
MilestonePlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Started5464
Completed5364
Not completed0100
Withdrew: Protocol deviation0100

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product (IP) or medicinal product. TEAEs were defined as AEs that started or worsened in severity on or after the infusion of IP. A serious TEAEs was any untoward clinical manifestation of signs, symptoms or outcomes (whether considered related to investigational product or not and at any dose) which resulted in death, was life-threatening, required inpatient hospitalization, prolongation of hospitalization, was an important medical event. TEAEs included both serious and non-serious AEs.

Time frame:
From date of signing informed consent up to end of study visit (Day 28)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious (TEAEs)
ParticipantsPlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Participants with TEAEs2242
Participants with Serious TEAEs0100
PrimaryNumber of Participants Who Developed Positive Binding Anti-ADAMTS13 and Inhibitory Anti-ADAMTS13 Antibodies to TAK-755

Measurement of Anti-ADAMTS13 antibodies can be used to assess whether the body's immune system has been stimulated to react to TAK-755. Binding Anti-ADAMTS13 antibodies measure antibodies that are able to bind to ADAMTS13, whether or not the antibodies have an effect on how well ADAMTS13 works. An inhibitory Anti-ADAMTS13 antibody is antibody that both binds to ADAMTS13 and able to affect how well ADAMTS13 works. Binding and Inhibitory anti-ADAMTS13 antibodies were categorized as pre-existing, treatment-induced, and treatment-boosted. Pre-existing: anti-ADAMTS13 antibodies were detected in the baseline sample prior to infusion with TAK-755. Treatment-induced: no anti-ADAMTS13 antibodies were detected in baseline sample but were detected in any sample drawn after TAK-755 infusion. Treatment-boosted: anti-ADAMTS13 antibodies were pre-existing and were detected at any time after TAK-755 infusion at titers that were at least 4 steps higher than the titers detected before TAK-755 infusion.

Time frame:
From date of signing informed consent up to end of study visit (Day 28)
Reported as:
Count of participants · Participants
Number of Participants Who Developed Positive Binding Anti-ADAMTS13 and Inhibitory Anti-ADAMTS13 Antibodies to TAK-755
ParticipantsPlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Pre-Existing Inhibitory Anti-ADAMTS13 Antibodies0000
Treatment-Induced Inhibitory Anti-ADAMTS13 Antibodies0000
Treatment-Boosted Inhibitory Anti-ADAMTS13 Antibodies0000
Pre-Existing Binding Anti-ADAMTS13 Antibodies1122
Treatment-Induced Binding Anti-ADAMTS13 Antibodies1110
Treatment-Boosted Binding Anti-ADAMTS13 Antibodies0000
SecondaryIncremental Recovery (IR) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

IR was defined as the ratio of maximum increase in plasma ADAMTS13 antigen or activity level to TAK-755 dose per body weight. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall. Here "IU/mL/IU/kg" refers to "International units per milliliter per international units per kilogram".

Time frame:
Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Reported as:
Mean · IU/mL/IU/kg
Incremental Recovery (IR) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
IU/mL/IU/kgTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Baseline-adjusted ADAMTS13 Activity0.022440 ± 32.30.025227 ± 33.40.018423 ± 33.6
Baseline-adjusted ADAMTS13 Antigen0.021809 ± 25.80.021925 ± 30.10.022012 ± 22.2
SecondaryObserved Maximum Concentration (Cmax) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

Cmax was a measure of the maximum amount of drug in the plasma after the dose was given. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

Time frame:
Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Reported as:
Geometric mean · international units per milliliter
Observed Maximum Concentration (Cmax) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
international units per milliliterTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Baseline-adjusted ADAMTS13 Activity0.90202 ± 33.52.0080 ± 33.22.9539 ± 33.6
Baseline-adjusted ADAMTS13 Antigen0.49848 ± 27.91.0382 ± 30.32.0392 ± 22.2
SecondaryTime to Reach Cmax (Tmax) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

Tmax was a measure of the time to reach the maximum concentration in the plasma after the drug dose. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

Time frame:
Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Reported as:
Median · hour
Time to Reach Cmax (Tmax) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
hourTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Baseline-adjusted ADAMTS13 Activity2.16 (0.32 to 3.03)1.08 (0.25 to 74.45)0.45 (0.32 to 1.18)
Baseline-adjusted ADAMTS13 Antigen0.45 (0.25 to 24.17)1.10 (0.28 to 3.48)0.83 (0.32 to 1.50)
SecondaryTerminal Half-Life (t1/2) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

t1/2 was the time required for a given drug concentration in the plasma to decrease by 50%. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

Time frame:
Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Reported as:
Mean · hour
Terminal Half-Life (t1/2) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
hourTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Baseline-adjusted ADAMTS13 ActivityNA ± NA54.56 ± 28.23042.22 ± 9.7253
Baseline-adjusted ADAMTS13 AntigenNA ± NA65.17 ± 41.72846.88 ± 16.821
SecondaryMean Residence Time From Zero to Infinite (MRT0-Inf) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

The MRT is the average time that the study product stays in the body (or plasma). The MRT0-Inf is defined as the average time from zero (pre-dose) extrapolated to infinite time (MRT0-inf). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

Time frame:
Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Reported as:
Mean · hour
Mean Residence Time From Zero to Infinite (MRT0-Inf) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
hourTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Baseline-adjusted ADAMTS13 ActivityNA ± NA118.6 ± 46.17087.54 ± 37.734
Baseline-adjusted ADAMTS13 AntigenNA ± NA116.3 ± 57.69969.48 ± 23.555
SecondaryMean Residence Time From Zero to 72 Hours Post-dose (MRT0-72) of ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

The MRT is the average time that the study product stays in the body (or plasma) and The MRT0-72 is defined as the average time from zero (predose) to 72 hours post-dose (MRT0-72). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755.

Time frame:
Baseline (Pre-dose), 0.25, 1, 3, 8, 24, and 72 hours post-dose

No measurements were reported for this outcome.

SecondaryArea Under the Curve From Zero to Time of Last Quantifiable Concentration (AUC0-Last) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

AUC0-Last was an area under the concentration-time curve from zero (pre-dose) to time of last quantifiable concentration. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

Time frame:
Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Reported as:
Geometric mean · hour* International unit per milliliter
Area Under the Curve From Zero to Time of Last Quantifiable Concentration (AUC0-Last) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
hour* International unit per milliliterTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Baseline-adjusted ADAMTS13 ActivityNA ± NA161.5 ± 28.1137.2 ± 36.1
Baseline-adjusted ADAMTS13 Antigen25.96 ± 32.979.05 ± 22.0105.7 ± 27.7
SecondaryArea Under the Curve Time Curve From Zero to 72 Hours Post-dose (AUC0-72) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

AUC0-72 was an area under the concentration-time curve from zero (predose) to 72 hours post-dose (AUC0-72). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

Time frame:
Baseline (Pre-dose), 0.25, 1, 3, 8, 24, and 72 hours post-dose
Reported as:
Geometric mean · hour* International unit per milliliter
Area Under the Curve Time Curve From Zero to 72 Hours Post-dose (AUC0-72) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
hour* International unit per milliliterTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Baseline-adjusted ADAMTS13 Activity19.77 ± 122.378.44 ± 36.892.41 ± 27.1
Baseline-adjusted ADAMTS13 Antigen17.91 ± 22.742.86 ± 9.573.20 ± 22.0
SecondaryArea Under the Curve From Zero to Infinite Time (AUC0-Inf) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

AUC0-inf was area under the concentration-time curve from zero (pre-dose) extrapolated to infinite time. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

Time frame:
Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Reported as:
Geometric mean · hour* International unit per milliliter
Area Under the Curve From Zero to Infinite Time (AUC0-Inf) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
hour* International unit per milliliterTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Baseline-adjusted ADAMTS13 ActivityNA ± NA190.1 ± 45.3152.5 ± 46.6
Baseline-adjusted ADAMTS13 AntigenNA ± NA88.34 ± 34.6114.0 ± 27.5
SecondarySystemic Clearance (CL) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC\[0-infinity\]). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

Time frame:
Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Reported as:
Geometric mean · liters per hour (L/h)
Systemic Clearance (CL) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
liters per hour (L/h)TAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Baseline-adjusted ADAMTS13 ActivityNA ± NA37.22 ± 64.374.35 ± 46.8
Baseline-adjusted ADAMTS13 AntigenNA ± NA51.28 ± 66.154.47 ± 54.47
SecondaryVolume of Distribution at Steady State (Vss) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755

Vss is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by MRT(0-inf)\*CL. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.

Time frame:
Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Reported as:
Geometric mean · liters
Volume of Distribution at Steady State (Vss) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
litersTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Baseline-adjusted ADAMTS13 ActivityNA ± NA3993 ± 48.25771 ± 17.2
Baseline-adjusted ADAMTS13 AntigenNA ± NA4682 ± 8.43661 ± 21.7
SecondaryChange From Baseline in Von Willebrand Factor: Antigen (VWF:Ag) at Specified Timepoints

Von Willebrand factor (vWF or VWF) is a protein that is one of several components of the coagulation system that work together to stop bleeding within the body. VWF:Ag measures the level of von Willebrand factor protein in the blood. The change from baseline in VWF:Ag concentration was measured at different time points. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.

Time frame:
Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Reported as:
Mean · Percentage of vWF Ag
Change From Baseline in Von Willebrand Factor: Antigen (VWF:Ag) at Specified Timepoints
Percentage of vWF AgPlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Change at 0.25 hours5.20 ± 23.774-29.47 ± 17.719-0.96 ± 32.870-16.27 ± 9.341
Change at 1 hour-9.90 ± 27.518-19.47 ± 10.1619.50 ± 20.1684.00 ± 12.139
Change at 3 hours-7.80 ± 12.301-18.27 ± 4.670-0.30 ± 22.744NA ± NA
Change at 8 hours-8.20 ± 14.24513.07 ± 20.433-0.24 ± 15.028NA ± NA
Change at 24 hours0.10 ± 17.11616.00 ± 34.11320.42 ± 18.7562.93 ± 24.981
Change at 72 hours-25.20 ± 27.6958.93 ± 43.27520.32 ± 25.3459.47 ± 25.026
Change at 120 hours-14.40 ± 37.183NA ± NA0.67 ± 29.7339.60 ± 47.411
Change at 168 hours-46.80 ± 23.708NA ± NA6.82 ± 29.703-20.40 ± 24.212
Change at 216 hours-44.10 ± 35.05613.87 ± 15.597-4.90 ± 43.425NA ± NA
Change at 288 hours-38.40 ± 33.032NA ± NA2.58 ± 32.591NA ± NA
Change at 648 hours-34.30 ± 45.276NA ± NA25.17 ± 30.641-26.93 ± 45.377
SecondaryChange From Baseline in Von Willebrand Factor:Ristocetin Cofactor Activity (VWF:RCo) At Specified Timepoints

Von Willebrand factor (vWF or VWF) is a protein that is one of several components of the coagulation system that work together, to stop bleeding within the body. VWF:RCo assay is a test that measures the activity of the VWF in a plasma sample in terms of how well it is able to clump platelets together in the presence of the antibiotic ristocetin. Change from baseline in vWF:RCo concentration was measured at different timepoints. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.

Time frame:
Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Reported as:
Mean · Percentage of vWF RCo
Change From Baseline in Von Willebrand Factor:Ristocetin Cofactor Activity (VWF:RCo) At Specified Timepoints
Percentage of vWF RCoPlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Change at 0.25 hours-6.78 ± 8.107-7.40 ± 10.802-6.06 ± 14.134-3.50 ± 13.365
Change at 1 hour-10.08 ± 11.346-7.80 ± 9.2426.63 ± 31.637-4.60 ± 8.285
Change at 3 hours-9.75 ± 5.047-20.80 ± 72.904-10.10 ± 7.833-7.00 ± 10.835
Change at 8 hours0.28 ± 34.209-34.80 ± 63.461-17.36 ± 34.424-8.00 ± 14.178
Change at 24 hours8.30 ± 5.58220.07 ± 36.0499.32 ± 18.590-1.20 ± 26.771
Change at 72 hours-8.03 ± 8.17620.17 ± 22.1678.60 ± 9.908-11.30 ± 11.895
Change at 120 hours4.33 ± 15.284NA ± NA-32.33 ± 50.707-0.55 ± 11.301
Change at 168 hours-9.87 ± 6.217NA ± NA0.97 ± 7.22715.00 ± 9.367
Change at 216 hours-15.90 ± 20.13213.20 ± 37.0919.35 ± 8.0057.08 ± 22.733
Change at 288 hours-22.33 ± 11.712NA ± NA8.58 ± 3.8127.83 ± 36.533
Change at 648 hours-17.03 ± 10.801NA ± NA9.43 ± 10.112-12.83 ± 83.921
SecondaryChange From Baseline in Platelet Count at Specified Timepoints

Blood samples were collected to analyze platelet count. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Thechange from baseline was calculated by subtracting the baseline value from the post-dose value.

Time frame:
Baseline (Pre-dose), 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Reported as:
Mean · 10^9 cells per liter
Change From Baseline in Platelet Count at Specified Timepoints
10^9 cells per literPlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Change at 3 hours-39.40 ± 35.7953.50 ± 27.111-42.80 ± 27.151-32.00 ± 19.511
Change at 8 hours-33.96 ± 29.53511.40 ± 24.309-38.42 ± 33.679-23.77 ± 25.325
Change at 24 hours-1.60 ± 38.94622.88 ± 36.779-11.83 ± 55.654-18.50 ± 25.265
Change at 72 hours-20.80 ± 61.37836.35 ± 19.025-7.10 ± 81.770-40.75 ± 64.691
Change at 120 hours4.50 ± 100.01840.83 ± 35.61718.94 ± 104.933-47.25 ± 61.927
Change at 168 hours-38.40 ± 94.64822.33 ± 58.04620.35 ± 122.803-73.33 ± 97.007
Change at 288 hours-42.00 ± 97.06017.67 ± 10.4086.17 ± 105.447-50.75 ± 70.296
Change at 648 hours-116.40 ± 232.11929.00 ± 27.3136.93 ± 77.0273.75 ± 51.344
SecondaryChange From Baseline in Plasma Free Hemoglobin at Specified Timepoints

The plasma free hemoglobin test measures the level of hemoglobin in the plasma (that is, not contained within the red blood cells). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.

Time frame:
Baseline (Pre-dose), 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Reported as:
Mean · milligrams per deciliter (mg/dL)
Change From Baseline in Plasma Free Hemoglobin at Specified Timepoints
milligrams per deciliter (mg/dL)PlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Change at 3 hours-5.23 ± 21.732-8.98 ± 23.930NA ± NA-106.15 ± 216.380
Change at 8 hours-11.28 ± 18.671-30.58 ± 34.219NA ± NA-147.80 ± 251.263
Change at 24 hours-3.88 ± 21.390-34.28 ± 36.621-44.77 ± 47.417-105.95 ± 214.072
Change at 72 hours-9.23 ± 22.105-44.93 ± 35.400-49.27 ± 47.550-108.30 ± 218.455
Change at 120 hours-14.70 ± 27.120NA ± NA-47.47 ± 48.187-98.18 ± 226.371
Change at 168 hours-10.60 ± 23.047-44.37 ± 50.024-41.37 ± 47.933-123.83 ± 274.097
Change at 288 hours-8.05 ± 25.683-46.47 ± 43.714-46.67 ± 47.0135.17 ± 4.319
Change at 648 hours13.30 ± 53.656-26.43 ± 45.465-43.83 ± 50.519-130.87 ± 265.316
SecondaryChange From Baseline in Plasma Thrombospondin Levels at Specified Timepoints

Change from baseline in plasma thrombospondin levels over time was reported. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.

Time frame:
Baseline (Pre-dose), 3, 8, 24, 72, 120, 168, 288, and 648 hours post-dose
Reported as:
Mean · nanograms per milliliter (ng/mL)
Change From Baseline in Plasma Thrombospondin Levels at Specified Timepoints
nanograms per milliliter (ng/mL)PlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Change at 3 hours840.4 ± 3979.24-628.5 ± 1420.49-1177.2 ± 1730.05-736.3 ± 860.29
Change at 8 hours-1892.8 ± 3500.43-604.5 ± 1763.64-1471.8 ± 1274.07-1290.0 ± 1060.98
Change at 24 hours-934.0 ± 1815.42-408.0 ± 1140.98-1077.0 ± 1699.60-1567.8 ± 957.61
Change at 72 hours-701.4 ± 2560.18-651.8 ± 1208.59-1080.0 ± 1945.58-1406.0 ± 843.31
Change at 120 hours-1075.0 ± 1357.88-1428.7 ± 1892.45-331.8 ± 3735.241351.8 ± 5880.93
Change at 168 hours-3886.0 ± 3999.22-847.0 ± 1728.41-1623.7 ± 1569.60-687.5 ± 1373.36
Change at 288 hours-103.0 ± 1974.37-482.0 ± 1150.09-1290.7 ± 1723.60-903.5 ± 1232.02
Change at 648 hours-2857.0 ± 4236.96-766.0 ± 1948.34-909.7 ± 1082.66525.5 ± 3358.11

Adverse events

Collected over From date of signing informed consent up to end of study visit (Day 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/5 (0%)0/5 (0%)2/5 (40%)
TAK-755: 40 IU/kg0/4 (0%)1/4 (25%)2/4 (50%)
TAK-755: 80 IU/kg0/6 (0%)0/6 (0%)4/6 (66.7%)
TAK-755: 160 IU/kg0/4 (0%)0/4 (0%)2/4 (50%)
Most frequent serious events
Most frequent serious events
EventPlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Sickle cell anaemia with crisisBlood and lymphatic system disorders0/51/40/60/4
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kg
Back painMusculoskeletal and connective tissue disorders0/50/42/60/4
HeadacheNervous system disorders0/50/42/60/4
Abdominal painGastrointestinal disorders0/50/40/61/4
Alanine aminotransferase increasedInvestigations0/51/40/60/4
Aspartate aminotransferase increasedInvestigations0/51/40/60/4
Blood lactate dehydrogenase increasedInvestigations0/51/40/60/4
DizzinessNervous system disorders0/51/40/60/4
Fibrin D dimer increasedInvestigations0/50/40/61/4
Foot fractureInjury, poisoning and procedural complications0/51/40/60/4
HypokalaemiaMetabolism and nutrition disorders0/51/40/60/4

Baseline characteristics

The Safety Analysis Set (SAS) included all participants randomized and who received any dose of the investigational product (IP).

Age, Categorical
Age, Categorical(Participants)PlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kgTotal
<=18 years00000
Between 18 and 65 years546419
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kgTotal
Female31318
Male233311
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kgTotal
Hispanic or Latino00000
Not Hispanic or Latino546419
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTAK-755: 40 IU/kgTAK-755: 80 IU/kgTAK-755: 160 IU/kgTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American546419
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

14 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 77202, United States
  • University of Colorado Sickle Cell Treatment and Research Center
    Aurora, Colorado 80045, United States
  • Sickle Cell Center
    Denver, Colorado 80262, United States
  • University of Illinois
    Chicago, Illinois 60612-4325, United States
  • Ochsner Health System
    New Orleans, Louisiana 70121, United States
  • Johns Hopkins University School Of Medicine
    Baltimore, Maryland 21218, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • East Carolina University
    Greenville, North Carolina 27858, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • University of Tennessee -- Memphis
    Memphis, Tennessee 38163-2116, United States
  • VCU Health - Research Parent
    Richmond, Virginia 23298, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Oct 2022, 36 months.

Results were first posted in Apr 2024, 1 year 5 months after primary completion.

Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 36 months is above that.

Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2019
First posted
Jun 25, 2019
StartActual
Oct 21, 2019
Primary completionActual
Oct 26, 2022
CompletionActual
Oct 26, 2022
Results first posted
Apr 23, 2024
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03997760
Lead sponsor
Shire
Collaborators
Takeda Development Center Americas, Inc.
Responsible party
Sponsor
First posted
Jun 25, 2019
Start date
Oct 21, 2019
Primary completion
Oct 26, 2022
Completion
Oct 26, 2022
Results posted
Apr 23, 2024
Last update
Apr 23, 2024

Study contacts

Study Director
study director · Takeda

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apadamtase alfa

Start the discussion